Baxter International Inc (BAX) stock
BAXNYSESurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 9/304% above fair value
$25.81+0.07 (+0.27%)
Close on Nov 13, 2026Market cap $13.35BP/E –Yield 2.01%
Baxter International r&d expenses
Research and development expenses are spending on new products and technology.
Baxter International's R&D Expenses for the twelve months ending Sep 30, 2026 was $519.00M, down 13.9% year over year. For fiscal 2025 it was $518.00M, down 12.2% from the year before. Over ten years it grew -1.5% a year on average. The highest annual figure on record is $1.08B in fiscal 2012.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $518.00M | -12.2% |
| FY2024 | Dec 31, 2024 | $590.00M | +13.9% |
| FY2023 | Dec 31, 2023 | $518.00M | +15.1% |
| FY2022 | Dec 31, 2022 | $450.00M | -15.3% |
| FY2021 | Dec 31, 2021 | $531.00M | +1.9% |
| FY2020 | Dec 31, 2020 | $521.00M | -12.4% |
| FY2019 | Dec 31, 2019 | $595.00M | -9.0% |
| FY2018 | Dec 31, 2018 | $654.00M | +6.3% |
| FY2017 | Dec 31, 2017 | $615.00M | -4.8% |
| FY2016 | Dec 31, 2016 | $646.00M | +7.1% |
| FY2015 | Dec 31, 2015 | $603.00M | -1.1% |
| FY2014 | Dec 31, 2014 | $610.00M | +4.8% |
| FY2013 | Dec 31, 2013 | $582.00M | -46.2% |
| FY2012 | Dec 31, 2012 | $1.08B | +14.3% |
| FY2011 | Dec 31, 2011 | $946.00M | +3.4% |
| FY2010 | Dec 31, 2010 | $915.00M | -0.2% |
| FY2009 | Dec 31, 2009 | $917.00M | +5.6% |
| FY2008 | Dec 31, 2008 | $868.00M | +14.2% |
| FY2007 | Dec 31, 2007 | $760.00M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $125.00M | +5.9% |
| Q2 FY2026 | Jun 30, 2026 | $129.00M | -3.7% |
| Q1 FY2026 | Mar 31, 2026 | $139.00M | -0.7% |
| Q4 FY2025 | Dec 31, 2025 | $126.00M | -40.3% |
| Q3 FY2025 | Sep 30, 2025 | $118.00M | -8.5% |
| Q2 FY2025 | Jun 30, 2025 | $134.00M | +3.1% |
| Q1 FY2025 | Mar 31, 2025 | $140.00M | +16.7% |
| Q4 FY2024 | Dec 31, 2024 | $211.00M | +66.1% |
| Q3 FY2024 | Sep 30, 2024 | $129.00M | -3.0% |
| Q2 FY2024 | Jun 30, 2024 | $130.00M | -21.2% |
| Q1 FY2024 | Mar 31, 2024 | $120.00M | -26.8% |
| Q4 FY2023 | Dec 31, 2023 | $127.00M | +6250.0% |
| Q3 FY2023 | Sep 30, 2023 | $133.00M | -11.9% |
| Q2 FY2023 | Jun 30, 2023 | $165.00M | +11.5% |
| Q1 FY2023 | Mar 31, 2023 | $164.00M | +9.3% |
| Q4 FY2022 | Dec 31, 2022 | $2.00M | -98.5% |
| Q3 FY2022 | Sep 30, 2022 | $151.00M | +17.1% |
| Q2 FY2022 | Jun 30, 2022 | $148.00M | +6.5% |
| Q1 FY2022 | Mar 31, 2022 | $150.00M | +17.2% |
| Q4 FY2021 | Dec 31, 2021 | $135.00M | 0.0% |
| Q3 FY2021 | Sep 30, 2021 | $129.00M | +4.9% |
| Q2 FY2021 | Jun 30, 2021 | $139.00M | +18.8% |
| Q1 FY2021 | Mar 31, 2021 | $128.00M | -12.3% |
| Q4 FY2020 | Dec 31, 2020 | $135.00M | -13.5% |
| Q3 FY2020 | Sep 30, 2020 | $123.00M | -14.6% |
| Q2 FY2020 | Jun 30, 2020 | $117.00M | -29.5% |
| Q1 FY2020 | Mar 31, 2020 | $146.00M | +13.2% |
| Q4 FY2019 | Dec 31, 2019 | $156.00M | -10.9% |
| Q3 FY2019 | Sep 30, 2019 | $144.00M | -13.3% |
| Q2 FY2019 | Jun 30, 2019 | $166.00M | -3.5% |
| Q1 FY2019 | Mar 31, 2019 | $129.00M | -8.5% |
| Q4 FY2018 | Dec 31, 2018 | $175.00M | -4.4% |
| Q3 FY2018 | Sep 30, 2018 | $166.00M | +10.7% |
| Q2 FY2018 | Jun 30, 2018 | $172.00M | +11.0% |
| Q1 FY2018 | Mar 31, 2018 | $141.00M | +11.0% |
| Q4 FY2017 | Dec 31, 2017 | $183.00M | +17.3% |
| Q3 FY2017 | Sep 30, 2017 | $150.00M | – |
| Q2 FY2017 | Jun 30, 2017 | $155.00M | – |
| Q1 FY2017 | Mar 31, 2017 | $127.00M | – |
| Q4 FY2016 | Dec 31, 2016 | $156.00M | – |
See a number that looks wrong?